Press release

Bayer partners with Luxsonic and OBIO® for enhanced use of Virtual Imaging Platform in clinical trials

June 25, 2024

June 25, 2024 (Toronto, ON) – Supported by OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, Bayer, and its Imaging Core Lab Services team, has partnered with Luxsonic Technologies, Inc. to evaluate and further enhance Luxsonic’s Virtual Imaging Platform (VIP) as a tool for use in clinical trials. This collaboration between Bayer, Luxsonic and OBIO®, will lead to the development of an enhanced clinical imaging tool for go/no-go decisions, and determination of efficacy, safety, and cost effectiveness of clinical trials.

Bayer’s Imaging Core Lab Services team is a digitally driven, key evidence-generating imaging solution provider for global pharmaceutical and biotechnology companies to facilitate the increasing role of imaging in drug and digital health product development. Luxsonic is dedicated to improving access to radiology services and creating better workflows through the use of augmented reality solutions. Luxsonic’s VIP™ software leverages ethical AI for image analysis and workflow optimization. The LSCTC Centre of Excellence accelerates the health science industry’s use of critical technologies such as ethical AI and fosters the evaluation and adoption of new health technologies across Ontario. This collaboration with Bayer will evaluate and further improve Luxsonic’s virtual reality technology platform to standardize practices, enhance quality, and increase efficiency in the expert radiology clinical trials workflows for diverse assessment criteria.

“Through further enhancement of an intelligent, collaborative, virtual reality-enabled radiology reading platform, Bayer Imaging Core Lab Services, Luxsonic and OBIO’s LSCTC Centre of Excellence aim to reduce product development cycle-time and increase quality and efficiency while reducing costs in clinical trials and Software as Medical Device development,” said Subrata Bose, Head of Bayer’s Imaging Core Lab Services.

“The partnership with Bayer and OBIO’s LSCTC Centre of Excellence represents an important milestone for our company. It’s a great opportunity to expand the use case of our VIP™ software into clinical trials imaging workflow with the goals of standardizing clinical trials practices, improving quality, and efficiency,” said Mike Wesolowski, Founder and CEO of Luxsonic.

“We are thrilled to welcome Bayer as a delivery partner for OBIO’s LSCTC Centre of Excellence to strengthen our shared commitment to advance health tech solutions from early-stage companies in Ontario,” said Dr. Maura Campbell, President and CEO of OBIO®. “This project with Luxsonic is a great example of how ethical AI can be implemented to improve clinical trial workflows and further support wider adoption of the technology in the global market.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to

About Bayer Imaging Core Lab Services

The Imaging Core Lab Services team at Bayer brings end-to-end imaging services to Bayer’s own clinical trials and those of the company’s arm’s length, including scientific consulting, cloud-based image acquisition, quality control, evaluation and management and real-time operational and quality metrics. The team’s network of over 40 core experts, and more than 100 additional internal and external associated physicians and radiologists, is currently involved in over 44 clinical trials and Software as Medical Device developments.

About Luxsonic

Luxsonic is a Canadian medical technology company that develops immersive, interactive, and intelligent software applications for extended reality devices.  Luxsonic’s flagship product, the Virtual Imaging Platform (VIP™) is a digital twin of the radiology reading room that equips physicians with all the tools they need to do their work in virtual reality. Designed for use with portable, all-in-one head mounted displays, Luxsonic VIP™ addresses the global shortage of medical imaging expertise, streamlining workflows and enhancing accessibility. By enabling better workflow, communication and knowledge sharing Luxsonic is working toward a world in which everyone has access to top tier radiology services and expertise. For more information, please visit

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation and implementation of new solutions using critical technologies through its Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, supported by the Government of Ontario. OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit and follow OBIO® on LinkedIn and X.


Media contacts:

Luxsonic Technologies Inc.

Communications Department
Bayer Inc.

Doriane Rey
Senior Manager, Marketing & Communications

For any additional questions, please contact us.